Intellia Therapeutics (NTLA) Total Current Liabilities (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Total Current Liabilities data on file, last reported at $76.4 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $76.4 million, down 32.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $76.4 million (down 32.11% YoY), and the FY2025 annual result was $103.9 million, down 6.29% from the prior year.
• Total Current Liabilities slipped to $76.4 million in Q1 2026 per NTLA's latest filing, from $103.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $131.1 million in Q3 2022 and troughed at $76.4 million in Q1 2026.
• A 5-year average of $107.0 million and a median of $105.1 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Current Liabilities jumped 107.75% in 2022, then sank 32.11% in 2026.
• A 5-year view of Total Current Liabilities shows it stood at $126.6 million in 2022, then dropped by 8.97% to $115.2 million in 2023, then slipped by 3.78% to $110.9 million in 2024, then dropped by 6.29% to $103.9 million in 2025, then decreased by 26.41% to $76.4 million in 2026.
• Business Quant data shows NTLA's Total Current Liabilities at $76.4 million in Q1 2026, $103.9 million in Q4 2025, and $93.7 million in Q3 2025.